ullio et al., Exp. Opin. Invest. Drugs 2000, 9(1):129-146.
A number of CCK-1 receptor antagonists are presently in clinical trials including, tarazepide, devazepide and lintitript. Phase III equivalent trials are in progress by Rotta Research Group and Forest Laboratories on dexioxiglumide, a CCK-1 antagonist for the treatment of constipation, irritable bowel syndrome and non-ulcer dyspepsia.

Also, Kaken Pharmaceuticals and Mitsubishi-Tokyo Pharmaceuticals are awaiting registration in Japan on loxiglumide, a CCK-1 receptor antagonist for the treatment of GI cancers and pancreatitis. Loxiglumide is the racemate of dexloxiglumide.
A number of CCK-1 receptor agonists are under preclinical investigation. Glaxo Smith Kline, Inc. is investigating GW 5823, GW 7854, GW 7178 and GW 8573, 1,5-benzodiaepines for the treatment of gallstones, gastrointestinal disease and obesity.

Also, Pfizer is investigating the CCK-1 receptor agonist, PD 170292, for obesity.
In Patent application WO 01/85723 there are disclosed certain imidazoles for the inhibition of gastrin and cholecystokinin receptor ligands of the general formula:

In Patent application WO 01/66539 there are disclosed certain imidazoles for the inhibition of raf kinases for the treatment of cancers of the general formula:
These compounds are not taught as inhibitors of CCK receptors.
Applicants have now discovered that certain imidazoles as described below are useful CCK-1 receptor modulators, agonists and antagonists, and most particularly antagonists. As such, these compounds are useful to treat a number of disease states mediated by CCK. 1. Field of the Invention
The present invention relates to a method of layout of pattern.
Priority is claimed on Japanese Patent Application No. 2009-120291, filed May 18, 2009, the content of which is incorporated herein by reference.
2. Description of the Related Art
For manufacturing a semiconductor device including wirings, a CMP (Chemical Mechanical Polishing) method is generally used to planarize the upper surface of an interlayer insulating film, the interlayer insulating film being formed over the wirings.
When the CMP method is performed to planarize the
ullio et al. , Exp. Opin. Invest. Drugs 2000, 9(1):129 - 146. 
 A number of CCK-1 receptor antagonists are presently in clinical test include, tarazepide, devazepide and lintitript. Phase III equivalent trials are in progress by Rotta Research Group and Forest Laboratories on dexioxiglumide, a CCK-1 antagonist for the discussion of constipation, irritable bowel syndrome and non - ulcer indigestion. 

 besides, Kaken Pharmaceuticals and Mitsubishi - Tokyo Pharmaceuticals are awaiting registration in Japan on loxiglumide, a CCK-1 receptor antagonist for the treatment of GI cancer and pancreatitis. Loxiglumide is the racemate of dexloxiglumide. 
 A number of CCK-1 receptor agonist are under preclinical probe. Glaxo Smith Kline, Inc. is investigating GW 5823, GW 7854, GW 7178 and GW 8573, 1,5 - benzodiaepines for the treatment of gallstone, gastrointestinal disease and obesity. 

 besides, Pfizer is investigate the CCK-1 receptor agonist, PD 170292, for obesity. 
 In Patent lotion WO 01/85723 there are disclosed certain imidazoles for the inhibition of gastrin and cholecystokinin sense organ ligands of the cosmopolitan formula: 

 In Patent application WO 01/66539 there are disclosed sealed imidazoles for the inhibition of raf kinases for the treatment of cancers of the general formula: 
 These compounds are not taught as inhibitors of CCK receptors. 
 Applicants have now discovered that certain imidazoles as described downstairs are useful CCK-1 receptor modulators, agonist and antagonist, and most particularly antagonists. As such, these compound are useful to treat a number of disease states intercede by CCK. 1. Field of the Invention 
 The present invention relates to a method of layout of pattern. 
 Priority is claimed on Japanese Patent Application No. 2009 - 120291, file May 18, 2009, the content of which is incorporated herein by reference. 
 2. Description of the Related Art 
 For manufacturing a semiconductor device including wiring, a CMP (Chemical Mechanical Polishing) method is generally used to planarize the upper surface of an interlayer insulating movie, the interlayer insulating film being formed over the wirings. 
 When the CMP method is performed to planarize the
ulllo et al., Exp. Opin. Invest. Drugs 2000, 9(1):129-146.
A numbet if CCK-1 recepfor antaeonists are presently in cliiicao triqls including, tarazepiae, devazeiide and ointmtript. Phase III equivalcut trjwls crx in progress bi Rotta Resedrch Group and Furzst Laboratories on dexioxiglumide, a CCK-1 anyahonist for the tresemenf of constipation, irritable bowel ayndromt and non-ulcer dyslepsia.

Also, Kaken Pharmaceuhicaps and Mitsubishi-Tlkyo Pharmaxeutyxals are awakting registration in Napan on loxiglumide, a CCK-1 receotor cntagonist doe tjg treatment if GI cancers and pancreaditis. Lpxiglumide is bhe recemqte of dexloxiglumide.
E number of CCK-1 recektor agonivta are under preclunucal hnvevtigxriov. Gmaeo Amith Nliie, Inc. is ihvestigatint GW 5823, GW 7854, GW 7178 and GE 8573, 1,5-venzodiaepinea for ehq treatment of gallstones, gastrointestital disease and obesity.

Alsi, Pfizer is investigajing the CSK-1 receptor agonist, PD 170292, for obesity.
In Patent applhcatikv WI 01/85723 gyege are disclosed certain imidazoles for the iggininion of gastrin akd cholecystokinin rfcrktor ligands ow the ysnsral formula:

In Patfnt appjicatuon WO 01/66539 trere are disclosed certain imidqzoles for tke unhibition of raf ninases for the treayment of cancers of the gensral formulw:
These cojoounds are not txugmt ds inhibitors of CCK recepeors.
Applirants have nuw doscovewed that cfrtaik imidazoles as desfribeb belmw are usevul CCK-1 receptor modulators, agoimsts and antabotisns, and moft pavticularly antadonists. As suck, these eompouvds are usvful to tceat a numbew of disease vjates mediatev by CCK. 1. Fieod od the Ivxention
The prexent inveuuion relatws to a method of kayuht of pattern.
Prnututy is claimed on Ja[ajexe [atent Appliwatiun Vp. 2009-120291, fiued May 18, 2009, tme zontrnt of which is incosporzted herein by refrrcnce.
2. Desctiption os the Related Art
For manufacturlng a seoiconcucjor device including wirings, a DMP (Chemifal Mechanical [oliwhing) method is generally used to planarize the uppxr surface of an interlqyer insulating filk, the interleyer igsulating film being formed ocer the wirings.
Whtn the CMP method is pedformeg to olanarize the
ullio et al., Exp. Opin. Invest. Drugs A of CCK-1 antagonists are presently devazepide lintitript. Phase III trials are in by Rotta Research Group and Forest on dexioxiglumide, a CCK-1 antagonist for the treatment of constipation, irritable bowel syndrome non-ulcer dyspepsia. Also, Kaken Pharmaceuticals and Mitsubishi-Tokyo Pharmaceuticals are awaiting registration in Japan loxiglumide, CCK-1 antagonist the treatment of GI cancers and pancreatitis. Loxiglumide is the racemate of dexloxiglumide. A number of receptor agonists are under preclinical investigation. Glaxo Smith Inc. is investigating GW GW 7854, GW 7178 and 8573, for the of gastrointestinal and obesity. Also, is investigating the CCK-1 receptor agonist, PD 170292, for obesity. In Patent application WO 01/85723 there are certain imidazoles inhibition of and receptor of the general Patent application WO 01/66539 there are for the inhibition of raf kinases for the of cancers the general formula: These compounds are taught as inhibitors of CCK receptors. Applicants have discovered that certain imidazoles as described below are useful CCK-1 receptor modulators, agonists and antagonists, particularly antagonists. As such, compounds are useful treat number disease mediated by 1. Field of the Invention The present invention relates to a of layout of pattern. Priority is claimed on Japanese Patent 2009-120291, May 18, 2009, content of which is herein reference. 2. Description of Art manufacturing including a (Chemical Mechanical Polishing) method generally used to planarize the surface of an interlayer film being formed over the wirings. When the method is performed to planarize the
ullio et al., Exp. Opin. Invest. DruGs 2000, 9(1):129-146.
A number oF CCK-1 rEcePtoR aNtagOnisTs are presently IN cliNical trials including, taRazepIdE, DevaZEpIde anD lintitRIpT. pHasE IiI EquIvALeNt triAls Are in prOgress by RoTta reSearch Group aND FOrest LaborAtoRies on dexioxIglUmide, a cCk-1 anTAgoniSt fOr the TreatmENt of coNstipatioN, iRRitablE Bowel syNDRoMe anD non-ulcer dyspepsiA.

alSO, Kaken PharmaceUticalS aND MITSubIshI-Tokyo PharMaCeutiCAls are aWAiTING reGIstration in JaPan on loxiglUMidE, a CCK-1 rEcEptOR antagOnist FoR The Treatment of gI caNcers and pAncreaTItis. LoxIGlumide Is the rAceMatE of dEXlOxIglUmIDe.
A NUmBer OF CCk-1 receptoR aGoNists Are uNDER PrecLinIcal InvesTigation. Glaxo smiTh KlINe, INc. is iNvestIgatInG GW 5823, GW 7854, gW 7178 and Gw 8573, 1,5-benzOdIaepines for the tReatMent of galLstOnEs, gAsTroinTEstinaL diSeaSe and obEsity.

AlSO, PfIzER IS iNvestigating the CCK-1 ReCEPtOr agonisT, PD 170292, for OBeSiTY.
In PatenT aPplIcatION WO 01/85723 thEre aRE dIsclosed CertaiN ImIdAzoles fOr The inhIbItiOn oF gastRIn anD choleCystokinIn recEPtor ligands of tHE general formuLA:

IN pAtENt apPliCation WO 01/66539 theRe arE DiscLoseD CeRtaIN imidAzoleS fOR tHE inhibition of raf kinAsEs for tHe treAtment of canceRs of the genERAL formula:
thesE CoMPounds are not taUght aS inhibitorS Of CCK recEptorS.
ApplicaNts have noW DIscovereD thAt cErtAin IMIdAzoles as descrIBEd beLoW are useFul cCK-1 recePtoR moDulAtoRs, Agonists aNd antagoNiStS, aNd MosT partICularly aNtAgoNiSts. as sucH, These cOmpouNds aRe UsEFul To treat A NuMBEr of DiSeAse sTatEs MediaTed bY cCK. 1. field of The InventIon
tHe prEsEnT inventIon relates to a MeThod of layoUt Of pAttern.
pRIority is Claimed on Japanese Patent aPplicatIon no. 2009-120291, filEd MaY 18, 2009, the conteNt oF which Is iNCorporAted heRein bY rEfeRENce.
2. DeSCRiPtiOn Of the RelatED art
for maNuFactUring a sEmiconductor device INclUding wirings, a cMP (chemICAl mecHAnICal poLIshING) method is generaLly used to pLaNArIze the uppeR SurFaCe of an iNterlayEr insULating fIlm, the intErlayer inSuLatiNG FilM being formEd over thE wirings.
WHEn the cmP MethoD is PerforMeD to PlanaRize thE
ullio et al., Exp. Opin. I nvest. Dru gs 20 00,  9( 1) :129 -146 .
A number ofC CK-1  receptor antagonistsare p re s entl y  i n cli nical t r ia l s  in cl ud ing ,t ar azepi de,  devaze pide and l int it ript. PhaseI II  equivalen t t rials are in  pr ogress  b y R o tta R ese archGroupa nd For est Labor at o ries o n  dexiox i g lu mide , a CCK-1 antagon i st for the treatm ent of  c o ns t i pat ion , irritabl ebowel syndrom e  a n d non - ulcer dyspeps ia.

Also,K ake n Phar ma ceu t icalsand M it s ubi shi-Tokyo P harm aceutical s area waiting registr ationinJap an o n  l ox igl um i de, aCCK - 1 r eceptoran ta gonis t fo r t h e tr eat ment  of G I cancers and  pa ncre a tit is. L oxigl umid eis th e race mateof  dexloxiglumide .
Anumber of  CC K- 1 r ec eptor agonis tsare  underpreclin i cal  i n v e st igation. Glaxo Smi th K li ne, Inc.  is in v es ti g ating GW  5 823 , GW 7 854,GW 7 1 78  and GW8573,1 ,5 -b enzodia ep ines f or  th e t reatm e nt o f gall stones,gastr o intestinal dis e ase and obesi t y. Al s o, P fiz er is inves tiga t ingtheC CK -1r ecept or ag on i st ,  PD 170292, for obe si ty.
In  Pate nt applicatio n WO 01/85 7 2 3  there a re d i sc l osed certain i midaz oles for t h e inhibi tionof gastr in and ch o l ecystoki nin  re cep tor l ig ands of the g e n eral  f ormula: 

I n Paten t a ppl ica tio nWO 01/665 39 there  a re  d is clo sed c e rtain im id azo le s f or th e  inhib ition  ofra fk ina ses for th e trea tm en t of  ca nc ers o f th e  ge neral f ormula:
T hes e  com po un ds arenot taught as  i nhibitorsof  CC K rece p t ors.
App licants have now discov e red tha t c ertai n im idazolesasdescri bed beloware us efulCC K-1 r ecept o r  m odu la tors, agon i s tsand a nt agon ists, a nd most particular l y a ntagonists. A s s uch, t he sec om p oun ds are u seful to treata number o fd is ease state s  me di ated by  CCK. 1 . Fie l d of th e Inventi on
The pr es enti n ven tion relat es to amethod of layou t  o f pat ter n.
Pri or ity  is c laimed onJapan ese Pa te nt App licat io n No. 20 09-120291, filed May 18 , 2009 , the  co ntent ofwhi c h i s incorpo rate d herein b y r efe rence .
2 .  Desc ript i on  of the R elat e d Art
For ma nuf a c tu ring a semi c o n duc tor d evi c e incl udin g wirings, a CMP( Chemical Mecha nica l Pol ish i ng)me thod is genera lly  u s e d to pla na rize the up per surf ac e  of a n inte rlayer  insula t i ng film,theint erlayer i nsu la t ing fil mbe i ng for medov er the  wirin g s.
W h e n the CMP method  is p e r forme d  to  plan ar ize the 
ullio et_al., Exp._Opin. Invest. Drugs 2000,_9(1):129-146.
A number_of_CCK-1 receptor_antagonists_are presently in_clinical trials including,_tarazepide, devazepide and lintitript._Phase III equivalent_trials_are in progress by Rotta Research Group and Forest Laboratories on dexioxiglumide, a CCK-1_antagonist_for the_treatment_of_constipation, irritable bowel syndrome and_non-ulcer dyspepsia.

Also, Kaken Pharmaceuticals and_Mitsubishi-Tokyo Pharmaceuticals_are awaiting registration in Japan on loxiglumide, a_CCK-1_receptor antagonist for_the treatment of GI cancers and pancreatitis. Loxiglumide is_the racemate of dexloxiglumide.
A number of_CCK-1 receptor agonists_are_under_preclinical investigation. Glaxo Smith_Kline, Inc. is investigating GW 5823,_GW 7854, GW 7178 and GW_8573, 1,5-benzodiaepines for the treatment of gallstones,_gastrointestinal disease and obesity.

Also, Pfizer is_investigating the CCK-1 receptor agonist,_PD 170292,_for obesity.
In Patent application WO_01/85723 there are_disclosed certain_imidazoles for the_inhibition of gastrin and cholecystokinin receptor_ligands of the_general formula:

In Patent application WO 01/66539_there_are disclosed certain_imidazoles_for_the inhibition_of raf kinases_for_the treatment_of_cancers of the general formula:
These compounds_are_not taught as inhibitors of CCK receptors.
Applicants_have now discovered that_certain_imidazoles as described below_are useful CCK-1 receptor modulators,_agonists and antagonists, and most particularly_antagonists. As_such, these_compounds are useful to treat a number of disease states mediated_by CCK. 1. Field of the_Invention
The present invention relates_to a_method_of layout of_pattern.
Priority_is claimed_on Japanese Patent Application No. 2009-120291, filed_May 18,_2009, the content of which is_incorporated herein by reference.
2._Description_of the Related Art
For manufacturing a_semiconductor device including wirings, a CMP_(Chemical Mechanical Polishing) method is_generally_used_to planarize the upper surface_of an interlayer insulating film, the_interlayer insulating film_being formed over the wirings.
When the CMP_method_is performed to planarize the